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Toll-like receptors (TLRs) are membrane-bound sensors that detect and respond to micro-
bial infection. Two studies in Cell, one in this issue, reveal how TLRs recognize their ligands. 
Kim et al. (2007) recently reported the structure of TLR4 bound to the accessory protein 
MD-2 and its antagonist, the drug eritoran. In this issue, Jin et al. (2007) describe the crystal 
structure of a complex between TLR1, TLR2, and a lipopeptide ligand.Nearly 20 years ago, Charles A. Jane-
way, Jr. proposed the existence of an 
innate immune recognition mecha-
nism that would identify conserved 
molecular structures expressed by 
microbes but not by eukaryotic hosts 
(Janeway, 1989). Such a recognition 
mechanism (termed pattern recogni-
tion) was hypothesized to enable a 
eukaryotic host to reliably detect a 
microbial infection. This hypothesis 
has since been confirmed with the 
identification of several families of pat-
tern recognition receptors, of which 
Toll-like receptors (TLRs) are the best 
characterized. All TLRs have a com-
mon domain organization, with an 
extracellular recognition domain con-
sisting of leucine-rich repeats (LRRs), 
a single transmembrane domain, 
and an intracellular Toll/IL-1 recep-
tor homology (TIR) signaling domain. 
TLR4 signaling is activated in response 
to bacterial lipopolysaccharide (LPS), 
the bacterial component responsible 
for endotoxic shock, whereas TLR2 
signaling is activated in response to 
a variety of both bacterial and fungal 
cell wall components. A variety of 
LRR domain-containing proteins have been crystallized, revealing that these 
domains form horseshoe-like struc-
tures with parallel β strands forming 
the concave face and the convex sur-
face composed of loops and a type of 
secondary structure known as 310 heli-
ces. The first structure of an LRR pro-
tein bound to its ligand—RNase inhibi-
tor bound to RNase—revealed that the 
protein-protein interactions occur at 
the concave face of the LRR horse-
shoe structure (Kobe and Deisenhofer, 
1995). However, although the micro-
bial ligands that activate TLRs are well 
known, the mechanism of TLR-medi-
ated pattern recognition has remained 
a mystery largely because TLRs have 
been refractory to crystallographic 
analysis.
In a recent issue of Cell, Kim, Lee, 
and their colleagues (Kim et al., 2007) 
report a clever new approach (termed 
the hybrid LRR technique) to crys-
tallize TLRs. They describe crystal 
structures of the TLR4 extracellular 
domain in complex with MD-2, a sol-
uble protein required for TLR4 signal-
ing. They also present the structure of 
TLR4 in complex with MD-2 bound to 
eritoran, an analog of LPS that antag-Cell 130, Septonizes TLR4 signaling. Due to this 
ability to antagonize TLR4 signaling, 
eritoran is currently in phase III clini-
cal trials for the treatment of severe 
sepsis. Meanwhile, in this issue, Jin, 
Lee, and their colleagues (Jin et al., 
2007) apply their method to crystal-
lize the complex of TLR1 and TLR2 
extracellular domains bound to a syn-
thetic lipopeptide agonist Pam3CSK4.
Their elegant strategy involves the 
use of hybrid proteins consisting of 
portions of mouse or human TLR-LRR 
domains fused to LRRs from variable 
lymphocyte receptor (VLR) proteins 
found in hagfish. Using a series of over-
lapping fusion constructs, Kim et al. 
were able to generate the first structure 
of the TLR4-LRR domain. One novel 
feature of the TLR4-LRR domain is that 
it possesses a three-domain architec-
ture in which the entire LRR can be 
subdivided into N-terminal, central, 
and C-terminal subdomains, each 
with characteristic structural features 
and with sharp demarcations at the 
subdomain junctions. Kim et al. (2007) 
also discovered that some TLR-VLR 
hybrids could bind to MD-2 or to MD-2 
in complex with eritoran and could also ember 21, 2007 ©2007 Elsevier Inc. 979
Figure 1. Models of Ligand-Induced TLR Activation 
(Left) Binding of the synthetic TLR2 agonist Pam3CSK4 to TLR2 and TLR1 occurs at the convex face of the extracellular LRR domain (Jin et al., 
2007). A single Pam3CSK4 molecule is sufficient to induce heterodimerization due to the presence of three acyl chains, two of which bind TLR2 in a 
hydrophobic pocket at the junction of the central and C-terminal LRR subdomains; the third acyl chain binds a hydrophobic pocket in TLR1. 
(Right) In contrast, binding of TLR4 to MD-2 occurs at the convex face of the TLR4 extracellular domain, at the junction of central and N-terminal 
LRR subdomains (Kim et al., 2007). LPS-induced TLR4 dimerization is presumed to require two molecules of MD-2 each bound to an individual 
LPS molecule, such that LPS-induced structural changes in MD-2 enable each MD-2 molecule to make simultaneous contacts with both TLR4-LRR 
domains. The LPS analog eritoran does not make direct contact with TLR4. It is presumed, therefore, that LPS also does not contact TLR4 directly, 
but rather induces dimerization through the interactions of MD-2 with TLR4.be crystallized. Together, these crystal 
structures provide a key advance in our 
understanding of how TLRs recognize 
their ligands. Intriguingly, TLR4 binds to 
MD-2 and to MD-2-eritoran at the con-
cave face of the LRR, at the junction of 
the N-terminal and central LRRs. This 
is in contrast to predictions of ligand 
binding from previous structures of the 
TLR3-LRR domain (Bell et al., 2005; 
Choe et al., 2005), as well as from the 
structure of TLR1-TLR2- Pam3CSK4 (Jin 
et al., 2007) (Figure 1).
One of the more striking aspects 
of the crystal structure of the com-
plete TLR4-MD-2-eritoran complex 
is that there are no direct contacts 
between eritoran and TLR4. Rather, 
the four acyl groups of eritoran 
occupy nearly 90% of the avail-
able space within the hydrophobic 
pocket in MD-2, whereas the phos-
phate groups of the diglucosamine 
backbone make ionic contacts with 
positively charged residues at the 
surface of the pocket. Indeed, this is 
very similar to the recent structure of 
MD-2 in complex with the LPS pre-
cursor lipid IVa (Ohto et al., 2007). 
In this structure, lipid IVa also occu-
pies virtually the entire volume of the 
deep hydrophobic pocket in MD-2, 
with the diglucosamine moieties 
exposed to solvent at the surface 
of the pocket. In contrast to eritoran 
and lipid IVa, which are TLR4 antag-
onists, most canonical agonist LPS 
structures (such as E. coli or Salmo-980 Cell 130, September 21, 2007 ©2007nella LPS) contain six acyl chains. It 
will be important to understand what 
structural changes occur in MD-2 in 
order to accommodate the increased 
size of agonist LPS. This is particu-
larly interesting because the eritoran-
MD-2 complex fails to induce TLR4 
dimerization, whereas MD-2 bound 
to LPS does. This suggests that 
as a general rule, TLR agonists will 
induce TLR dimerization, whereas 
antagonists are likely to interfere 
with dimerization. Indeed, analyses 
by others (Kobayashi et al., 2006) as 
well as Kim et al. (2007) demonstrate 
that residues of MD-2 not involved 
in direct contact with either LPS or 
TLR4 play a key role in homodimer-
ization of the TLR4-MD-2 complex in 
the presence of LPS. Kim et al. thus 
propose a model in which the inter-
action of LPS with MD-2 bound to 
one TLR4 protein results in allosteric 
changes in MD-2 that promote the 
interaction of MD-2 with the central 
or C-terminal domain of a second 
TLR4 protein.
The second study by Lee and col-
leagues (Jin et al., 2007) indicates that 
like TLR4, both TLR1 and TLR2 are 
structurally “atypical” members of the 
LRR superfamily, as their LRR domains 
can be subdivided into N-terminal, 
central, and C-terminal subdomains, 
each of which has a characteristic β 
sheet conformation. However, in con-
trast to MD-2 binding of TLR4, bind-
ing of triacylated lipopeptide to TLR2  Elsevier Inc.occurs in a lipid-binding pocket that is 
formed at the convex face of the junc-
tion between the central and C-termi-
nal LRR domains. This pocket accom-
modates two of the acyl chains of the 
synthetic TLR agonist, Pam3CSK4, 
whereas a similar lipid-binding pocket 
in TLR1—also at the junction between 
the central and C-terminal LRR 
domains—accommodates the third 
acyl chain. This structure explains the 
requirement for TLR2-TLR1 heterodi-
merization for the response to triacyl-
ated lipopeptides. Despite the lack of a 
third acyl group, diacylated Pam2CSK4 
interacts with the lipid-binding pocket 
of TLR2 in virtually the same fashion 
as Pam3CSK4. Interestingly, modeling 
of TLR6 by Jin et al. suggested that it 
lacks the lipid-binding pocket of TLR1. 
It will therefore be particularly enlight-
ening to understand how TLR2-TLR6 
dimerization occurs. TLR6 may inter-
act directly with the peptide portion 
of diacylated lipopeptides, or with the 
glycerophosphate moiety of lipotei-
choic acid (LTA), which are exposed to 
solvent and may therefore form ionic 
contacts with residues from TLR6.
A particularly surprising aspect of 
the two sets of findings by Lee and col-
leagues is that the mode of ligand rec-
ognition by TLR4-MD-2 and TLR1/TLR2 
is completely different in terms of the 
site of ligand binding and the require-
ment for accessory proteins (Figure 
1). It has been puzzling how TLRs can 
detect multiple ligands that are struc-
turally unrelated to each other. One 
possibility suggested by these studies 
is that protein ligands (such as flagel-
lin or porins) may bind their respec-
tive TLRs in a manner exemplified by 
MD-2, that is, in the concave surface 
of the TLR ectodomains. The nonpro-
tein TLR ligands (including nucleic acid 
ligands), on the other hand, are likely to 
bind in the manner exemplified by the 
Pam3CSK4, that is, at the convex face 
of a pair of ectodomains.
Crystallization of TLRs in complex 
with their ligands has eluded the field 
of TLR biology for nearly a decade. 
The papers by Kim et al. and Jin et 
al. reveal a new approach that is likely 
to be applicable to the crystalliza-Initial evidence for the involvement of 
the DISC1 (Disrupted-in-Schizophre-
nia 1) gene in schizophrenia was based 
primarily on a large Scottish pedigree 
where the gene was disrupted by a 
chromosomal translocation. Several 
other linkage and association studies 
also connect DISC1 to schizophrenia 
and to other psychotic and affective 
disorders (Mackie et al., 2007). Thus 
understanding the role of the DISC1 
gene product could reveal insights 
into the pathophysiology of psychiat-
ric illness. Analysis of DISC1 function 
supports a role in regulating neuro-
nal migration and structural plasticity. 
DISC1 expression is highest during 
the neurogenic period of development 
and in neurogenic regions in the adult 
rodent brain. Although much work has 
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The gene DISC1 (Disrupted-in-S
In this issue, Duan et al. (2007
integration of newly generated 
appears to have opposite effection of additional TLRs. TLR4-MD-2 
still remains to be cocrystallized with 
its agonist ligand, LPS; however, the 
cocrystal of TLR2-TLR1-Pam3CSK4 
reveals the first structural basis for 
ligand-induced receptor dimerization 
of TLRs. These two papers together 
also provide a structural basis for the 
possible generation of hybrid TLRs 
that may possess new ligand binding 
and response properties.
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